Eribulin Mesylate

Product Information

  • Proprietary Name: Nibulin®
  • Generic Name: Eribulin Mesylate
  • Dosage Form: Vial
  • Strengths: 1 mg/2 ml
  • Indications: Locally Advanced or Metastatic Breast Cancer and Liposarcoma



Eribulin Mesylate is indicated for the treatment of patients with locally advanced or metastatic breast cancer and liposarcoma.

Ready to get started?

Curious about a specific position? Sign up for it.
© NanoAlvand. All rights reserved. Powered by ِDGN.